AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Sara M TolaneyArlene ChanKatarina PetrakovaSuzette DelalogeMario CamponeHiroji IwataParvin F PeddiPeter A KaufmanElisabeth De KermadecQianying LiuPatrick CohenGautier PauxLei WangNils TernèsEric BoitierSeock-Ah ImPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
mutation. Efficacy and safety with amcenestrant were consistent with the standard of care for second-/third-line ET for ER+/HER2- aBC.
Keyphrases
- estrogen receptor
- phase ii study
- epidermal growth factor receptor
- open label
- placebo controlled
- tyrosine kinase
- phase iii
- advanced non small cell lung cancer
- phase ii
- clinical trial
- endothelial cells
- double blind
- healthcare
- palliative care
- locally advanced
- study protocol
- quality improvement
- induced pluripotent stem cells
- pluripotent stem cells
- randomized controlled trial
- squamous cell carcinoma
- young adults
- rectal cancer
- chronic pain